you're reading...
Economic and Social Policies, PUBLICATIONS

Medicinal products in the European Union: The legal framework for medicines for human use

Written by Nicole Scholz

A high level of protection for human health is a central objective of European Union (EU) public health policy. To guarantee this objective, high standards of quality and safety for medicinal products are essential. Although pharmaceuticals are primarily regulated at the national level by the Member States, there is a large body of EU legislation in the field.

Medicinal products in the European Union: The legal framework for medicines for human use

© Andrzej Tokarski / Fotolia

A medicine must be authorised before it can be placed on the market. In the EU regulatory system, there are several routes for obtaining marketing authorisation: either at European level (the centralised procedure) or at national level (the decentralised and mutual-recognition procedures). Under the centralised procedure, EU authorisation is granted by the European Commission via an application to the European Medicines Agency (EMA). The EMA coordinates the assessment of the quality, safety and efficacy of medicinal products. It draws up scientific opinions for the evaluation of such medicines for the EU institutions and the Member States. The EMA also coordinates Member States’ activities in connection with the monitoring of medicines for safety once they have been placed on the market (pharmacovigilance), and manages the internet-based information system created to this effect. In addition, the EMA coordinates Member States’ supervision and inspection of manufacturers.

Two special authorisation procedures exist outside the conventional routes: Article 58 applications (for medicines used exclusively outside the EU) and the procedure for compassionate use. There are specific regulatory rules for ‘orphan medicines’, as well as paediatric, geriatric, advanced-therapy, herbal, homeopathic and non-prescription medicines.

A number of instruments have been put in place to guarantee that a medicinal product fulfils the legal requirements in terms of quality, safety and efficacy. These are the principles of good manufacturing, good distribution, and good pharmacovigilance practices. They are complemented by information for patients and protection against
falsified medicines. With a view to allowing early access to medicines, a new concept – the adaptive pathways approach – has recently taken shape. It is based on existing regulatory procedures such as compassionate use, and involves progressive access to medicines in advance of full authorisation. This could particularly benefit patients who have a medical condition not adequately addressed by an existing therapy.

Read this In-depth analysis on Medicinal products in the European Union: The legal framework for medicines for human use in PDF



  1. Pingback: Online medicines – between legality and illegality - farmacist - July 20, 2015

  2. Pingback: Medicamente online - intre legalitate si ilegalitate - July 20, 2015

Leave a Reply

Download the EPRS App

EPRS App on Google Play
EPRS App on App Store
What Europe Does For You
EU Legislation in Progress
Topical Digests
EPRS Podcasts

Follow Blog via Email

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 3,537 other subscribers

RSS Link to Members’ Research Service

Disclaimer and Copyright statement

The content of all documents (and articles) contained in this blog is the sole responsibility of the author and any opinions expressed therein do not necessarily represent the official position of the European Parliament. It is addressed to the Members and staff of the EP for their parliamentary work. Reproduction and translation for non-commercial purposes are authorised, provided the source is acknowledged and the European Parliament is given prior notice and sent a copy.

For a comprehensive description of our cookie and data protection policies, please visit Terms and Conditions page.

Copyright © European Union, 2014-2019. All rights reserved.

%d bloggers like this: